LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Начало・Списък с акции・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Затворен

СекторЗдравеопазване

1.84 2.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.77

Максимум

1.88

Ключови измерители
By Trading Economics
Приходи	-5.9M 247K
Продажби	5.1M 62M
Марж на печалбата	0.395
Служители	181
EBITDA	-6.1M 7.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+259.28% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-326M 562M
Предишно отваряне	-0.38
Предишно затваряне	1.84

Настроения в новините

By Acuity

58%

42%

314 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

2.345 / N/A Подкрепа & съпротива

Akebia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.11.2025 г., 23:59 ч. UTC

Печалби

Singtel's 1st Half Net Profit Surges

11.11.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11.11.2025 г., 22:21 ч. UTC

Печалби

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11.11.2025 г., 23:52 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11.11.2025 г., 23:44 ч. UTC

Печалби

Singtel's 1H Net Profit Surges

11.11.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11.11.2025 г., 23:18 ч. UTC

Печалби

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11.11.2025 г., 23:15 ч. UTC

Печалби

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11.11.2025 г., 23:14 ч. UTC

Печалби

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11.11.2025 г., 23:12 ч. UTC

Печалби

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11.11.2025 г., 23:11 ч. UTC

Печалби

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11.11.2025 г., 23:10 ч. UTC

Печалби

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

11.11.2025 г., 21:46 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11.11.2025 г., 21:41 ч. UTC

Печалби

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11.11.2025 г., 21:40 ч. UTC

Печалби

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: Final Dividend 49 Australian Cents/Share

11.11.2025 г., 21:37 ч. UTC

Печалби

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11.11.2025 г., 21:36 ч. UTC

Печалби

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11.11.2025 г., 21:35 ч. UTC

Печалби

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Adj EPS 79c >ALC

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Rev $2.61B >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q EPS 48c >ALC.EB

Сравнение с други в отрасъла

Ценова промяна

Akebia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

259.28% нагоре

12-месечна прогноза

Среден 6 USD 259.28%

Висок 7 USD

Нисък 5 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Akebia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Akebia Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.345 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

314 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.